Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Sciences Ltd.

Division of Roivant Sciences GmbH
www.axovant.com

Latest From Axovant Sciences Ltd.

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Financing StartUps and SMEs

Urovant’s Vibegron Faces Tough Commercial Climb Despite Phase III Success

Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.

Gynecology & Urology Clinical Trials

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors

Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.

Artificial Intelligence Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Roivant Sciences GmbH
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    Gregory M Weinhoff, MD, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, Chief Business Officer
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, CMO
    Paul Korner, MD, SVP, Clin. Dev.
  • Contact Info
  • Axovant Sciences Ltd.
    Phone: 1-295-5950
    20-22 Bedford Row
    London, X0 WC1R 4J
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register